Uterine Leiomyoma (Uterine Fibroids) Pipeline by Top Companies Analysis, Review 2019

Posted on 2019-10-01 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Oct-01 — /EPR Network/ —Market Research Hub (MRH) has actively discoursed a new study titled “Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2019”, added to its vast online repository. The main motive of this assessment is to present clear insights about the growth factor experienced across the Uterine Leiomyoma (Uterine Fibroids) during the forecast period. Readers can access vital information associated to prime market facets such as market size, market share, market drivers, future trends, challenges, opportunities and sales channels. Furthermore, the availability of competitive developments including leading market players make the report a rich data source for investors and new entrants.

Get Sample Copy at https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519477

Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H2 2019

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H2 2019, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 1, 3, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
– The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Browse Complete Report at https://www.marketresearchhub.com/report/uterine-leiomyoma-uterine-fibroids-pipeline-review-h2-2019-report.html

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Leiomyoma (Uterine Fibroids) – Overview
Uterine Leiomyoma (Uterine Fibroids) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Uterine Leiomyoma (Uterine Fibroids) – Companies Involved in Therapeutics Development
AbbVie Inc
Addex Therapeutics Ltd
Auritec Pharmaceuticals Inc
Bayer AG
BioSpecifics Technologies Corp
GeneScience Pharmaceuticals Co Ltd
Immunitor Inc
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Richter Gedeon Nyrt
Takeda Pharmaceutical Co Ltd
Uterine Leiomyoma (Uterine Fibroids) – Drug Profiles
collagenase clostridium histolyticum – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-30916 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Progesterone Receptor for Uterine Fibroids – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-313 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elagolix sodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linzagolix choline – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-403 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Continued………. #@

Make an Enquiry about This Report https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519477

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick